Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

BACKGROUND: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. METHODS: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. RESULTS: In all patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamian, Francesca, Lin, Shao-Lee, Lee, Edmund, Kikuchi, Toyoko, Gilleaudeau, Patricia, Sullivan-Whalen, Mary, Cardinale, Irma, Khatcherian, Artemis, Novitskaya, Inna, Wittkowski, Knut M, Krueger, James G, Lowes, Michelle A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906741/
https://www.ncbi.nlm.nih.gov/pubmed/17555598
http://dx.doi.org/10.1186/1479-5876-5-27
Descripción
Sumario:BACKGROUND: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. METHODS: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. RESULTS: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7(- )CD45RA(-)) (mean 63% reduction) for both CD4(+ )and CD8(+ )Tem, while central memory T cells (Tcm) (CCR7(+)CD45RA(-)) were less affected, and naïve T cells (CCR7(+)CD45RA(+)) were relatively spared. Circulating CD8(+ )effector T cells and Type 1 T cells (IFN-γ-producing) were also significantly reduced. CONCLUSION: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

Ejemplares similares